Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 8,340 shares at $12.23 ($102K) on 2025-12-23, disclosed to the SEC on 2025-12-30.
Scheduled sale ($102k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.23 | 4,170 | $51K | 50.0% |
| 2 | $12.23 | 4,170 | $51K | 50.0% |
| Total | $12.23 avg | 8,340 | $102K | 100% |
| Filing → |
| CTNM | SELL | 2026-06-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-05-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-04-06 | $56K | — | Filing → |